MSX2 and breast carcinoma: However, Barnes et al. found that Msx2 repressed the activity of the prometastatic bone sialoprotein (BSP) in breast cancer cell lines [18], casting doubt on a proinvasive role for Msx2, as BSP is associated with poor outcome in breast cancer [19].